Compare AMTB & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | CRON |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | AMTB | CRON |
|---|---|---|
| Price | $22.73 | $2.63 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.75 | N/A |
| AVG Volume (30 Days) | 303.6K | ★ 1.4M |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.26 | 0.09 |
| Revenue | ★ $394,190,000.00 | $132,357,000.00 |
| Revenue This Year | $8.81 | $17.63 |
| Revenue Next Year | $7.78 | $30.76 |
| P/E Ratio | ★ $17.81 | $27.62 |
| Revenue Growth | ★ 43.98 | 19.00 |
| 52 Week Low | $15.62 | $1.60 |
| 52 Week High | $24.30 | $3.43 |
| Indicator | AMTB | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 53.80 |
| Support Level | $21.97 | $2.57 |
| Resistance Level | $23.55 | $2.74 |
| Average True Range (ATR) | 0.70 | 0.09 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 67.68 | 72.97 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.